Building on the observation that TOPBP1 may be a potential “HRDness inducer,” [13, 47] we used olaparib, typically administered to HR-deficient tumor patients, and narrowed its use to 5–7% of patients with PDAC with a pathogenic germline BRCA mutation, aiming to establish a new PDAC treatment strategy. This evidence concerns the gene TOPBP1 and neoplasm.